Technical Analysis for COGT - Cogent Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | -2.06% | |
| Earnings Movers | Other | -2.06% | |
| Outside Day | Range Expansion | -2.06% | |
| Above Upper BB | Strength | -2.06% | |
| Overbought Stochastic | Strength | -2.06% | |
| Up 3 Days in a Row | Strength | -2.06% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 19 hours ago |
| 1.5x Volume Pace | about 23 hours ago |
| Down 3% | about 23 hours ago |
| Down 2 % | about 23 hours ago |
| Down 1% | about 23 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Cogent's most advanced program, PLX9486, is a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent is headquartered in Cambridge, MA.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Gastrointestinal Stromal Tumors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Gastrointestinal Stromal Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.5 |
| 52 Week Low | 3.67 |
| Average Volume | 1,567,029 |
| 200-Day Moving Average | 8.06 |
| 50-Day Moving Average | 6.76 |
| 20-Day Moving Average | 6.82 |
| 10-Day Moving Average | 6.99 |
| Average True Range | 0.48 |
| RSI (14) | 61.09 |
| ADX | 19.01 |
| +DI | 28.41 |
| -DI | 16.27 |
| Chandelier Exit (Long, 3 ATRs) | 6.40 |
| Chandelier Exit (Short, 3 ATRs) | 7.31 |
| Upper Bollinger Bands | 7.81 |
| Lower Bollinger Band | 5.83 |
| Percent B (%b) | 0.89 |
| BandWidth | 29.12 |
| MACD Line | 0.23 |
| MACD Signal Line | 0.10 |
| MACD Histogram | 0.1312 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.21 | ||||
| Resistance 3 (R3) | 8.22 | 8.02 | 8.11 | ||
| Resistance 2 (R2) | 8.02 | 7.87 | 8.02 | 8.07 | |
| Resistance 1 (R1) | 7.81 | 7.77 | 7.72 | 7.80 | 8.04 |
| Pivot Point | 7.62 | 7.62 | 7.57 | 7.61 | 7.62 |
| Support 1 (S1) | 7.41 | 7.46 | 7.31 | 7.40 | 7.16 |
| Support 2 (S2) | 7.21 | 7.37 | 7.21 | 7.13 | |
| Support 3 (S3) | 7.00 | 7.21 | 7.09 | ||
| Support 4 (S4) | 6.99 |
